MAP Kinase Activation Causes Deadly Brain Tumor

Due to brain sensitivity and the risks associated with performing surgery, brain tumors remain one of the deadliest forms of cancer. New findings could lead to targeted treatment options for patients with brain tumors that cannot be surgically removed.

Chordoid gliomas, a rare type of brain cancer, are notoriously dangerous to remove. The discovery of a gene that may play a role in the development of chordoid gliomas may lead to an effective therapy, according to a study published by Nature Communications.

Chordoid gliomas grow in the third ventricle of the brain, which is filled with fluid that provides cushioning to the brain. The cancer progresses slowly, but its proximity to the hypothalamus makes it almost impossible to remove, leaving patients with few effective treatment options, according to the study.

In the study, the authors examined the genome sequences of 13 chordoid gliomas and discovered the mutation of a single gene across every tumor.

The gene, PRKCA, plays a key role in MAP kinase, a growth pathway that is dormant in healthy brain cells. Mutations of PRKCA activate the MAP pathway, causing the cells to divide rapidly and form a cancerous tumor.

Although PRKCA has not been identified in any other type of cancer, most human tumors develop from a mutation that effects the MAP kinase in some way, according to the authors.

Because the MAP pathway is known to be involved with cancer development, drugs that target it have already been FDA-approved and launched.

The researchers then tested trametinib—an MEK inhibitor approved for melanoma—on brain cells with a PRKCA mutation. Researchers discovered that trametinib effectively stopped the development of tumors from the mutation in brain cells.

The authors noted that this finding is groundbreaking and may open the door to new therapies for chordoid gliomas.

“Precision medicine for cancer is based on identifying the DNA alterations that are behind the tumor. Then we can figure out what that DNA alteration does inside the cells to cause the tumors to form,” said lead researcher David Solomon, MD, PhD. “Once we know that, then we can predict drugs to give to inhibit the activated pathways and stop the tumor growth.”

The authors are currently working to design a nationwide clinical trial for patients with chordoid gliomas.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Daily doses of sildenafil (Viagra) cut the development of polyps by 50% in mouse models.
A cellular process could be key to lowering levels of the Huntington disease protein.
The addition of atezolizumab (Tecentriq) to chemotherapy may improve outcomes for patients with advanced non-small cell lung cancer.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.